NL-OMON53229RecruitingPhase 4
Population pharmacokinetics of mycophenolate mofetil in autoimmune diseases - PPMMAD
Zuyderland Medisch Centrum0 sites60 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Phase 4
- Status
- Recruiting
- Sponsor
- Enrollment
- 60
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •Mycophenolate mofetil use in autoimmune diseases
Exclusion Criteria
- •age < 16 years
- •Patient with serum levels of MPA not measured at steady state (<1 week of
- •doses-adjustment)
- •Patients using the MPA preparation mycophenolic acid (Myfortic®)
Investigators
Similar Trials
Active, not recruiting
Not Applicable
Pharmacokinetics of Mycophenolate Mofetil in de novo lung allograft recipients - CELMACSEUCTR2009-012231-15-DERoche Pharma AG
Completed
Not Applicable
Pharmacokinetic Study of mycophenolate mofetil combined with rituximab in patients with Childhood-onset Complicated Frequently Relapsing or Steroid-dependent Nephrotic SyndromeChildhood-onset Complicated Frequently Relapsing or Steroid-dependent Nephrotic SyndromeJPRN-UMIN000016764Japanese Study Group of Kidney Disease in Children79
Active, not recruiting
Not Applicable
Vergleich der Pharmakokinetik von Mycophenolatmofetil und Mycophenolat-Natrium bei Calcineurininhibitor-frei behandelten nierentransplantierten Patienten.EUCTR2009-012355-15-DERoche Pharma AG
Completed
Phase 3
A Study of Mycophenolate Mofetil (CellCept) in Lung Transplant RecipientsLung TransplantationNCT01014442Hoffmann-La Roche68
Completed
Not Applicable
Safety and efficacy of mycophenolate mofetil in pediatric renal transplantatioISRCTN89278733Erasmus Medical Center (The Netherlands)44